Aardvark Therapeutics held its Annual Meeting on August 14, 2026, with 54.79% of outstanding shares voting. Stockholders elected Victor Tong, Jr. and Jeffrey Chi as Class I directors and ratified BDO USA, P.C. as the independent auditor. Crucially, shareholders approved the repricing of certain outstanding stock options under the Company's equity incentive plans. This corporate action modifies existing compensation agreements for eligible participants. Aardvark Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Aardvark Therapeutics reported second quarter 2026 financial results, including a net loss of $14.4 million and cash reserves of $73.9 million sufficient to fund operations into late 2027. The company terminated its Phase 3 HERO and Open Label Extension trials for ARD-101 in June 2026 following a full clinical hold placed by the FDA in May 2026. Aardvark plans to assess unblinded data from these trials in the third quarter of 2026 to determine next steps while maintaining active discussions with regulators regarding the clinical hold.

Aardvark Therapeutics, Inc. entered into retention bonus agreements with CFO/COO Nelson Sun and CMO Dr. Manasi Jaiman on June 10, 2026. Mr. Sun is entitled to a $346,500 cash bonus, including a $198,000 annual bonus and $153,000 retention bonus, payable on January 1, 2027. Dr. Jaiman is entitled to a $357,000 cash bonus, including a $204,000 annual bonus and $153,000 retention bonus, payable on January 1, 027. Aardvark Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.